Mahesh Swaminathan, M.B., B.S.

Peer-Reviewed Articles

1. Bazinet A, Montalban-Bravo G, Bataller A, Hammond D, Loghavi S, Chien K, Sasaki K, Bouligny I, Swaminathan M, Jen WY, Popat U, Kadia T, DiNardo C, Jabbour E, Short N, Daver N, Ravandi F, Garcia-Manero G. Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome. Leukemia 39(11):2820-2824, 2025. e-Pub 2025. PMID: 40913105.
2. Azevedo RS, Braish J, Gener-Ricos G, Tang G, Sasaki K, Montalban-Bravo G, Jabbour E, Ohanian M, Yilmaz M, Haddad FG, Chien K, Ishizawa J, Short NJ, Maiti A, Swaminathan M, Kantarjian H, Borthakur G, Kadia TM. Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia. Leuk Lymphoma:1-5, 2025. e-Pub 2025. PMID: 41173347.
3. Montalban-Bravo G, Loghavi S, Li Z, Chien K, Kanagal-Shamanna R, Bataller A, Natu A, Gurney M, Bazinet A, Hammond D, Sasaki K, Borthakur G, Swaminathan M, DiNardo C, Kadia T, Ravandi F, Daver N, Short N, Pemmaraju N, Issa G, Lasho TL, Finke CM, Al-Kali A, Csizmar C, Alkhateeb H, Gangat N, Mangaonkar AA, Bueso-Ramos C, Tefferi A, Kantarjian H, Garcia-Manero G, Patnaik MM. Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia. Blood Adv 9(19):5105-5117, 2025. e-Pub 2025. PMID: 40644618.
4. Bazinet A, Bataller A, Montalban-Bravo G, Chien K, Sasaki K, Jen WY, Swaminathan M, Kadia T, DiNardo C, Ravandi F, Garcia-Manero G, Kantarjian H. PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes. Haematologica, 2025. e-Pub 2025. PMID: 40605709.
5. Berkman AM, Andersen CR, Puthenpura V, Short NJ, Merriman K, Swaminathan M, Cuglievan B, McCall D, DiNardo C, Nunez C, Jain N, Kadia T, Issa G, Gibson A, Garcia MB, Livingston JA, Parsons S, Hildebrandt MAT, Roth ME. Risk of early death after acute leukemia diagnosis among adolescents and young adults. JNCI Cancer Spectr 9(4), 2025. e-Pub 2025. PMID: 40579211.
6. Pemmaraju N, Phan LH, Fell G, Luskin MR, Swaminathan M, Pierce S, DiNardo C, Maiti A, Konopleva M, Lane AA. Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN. Blood Neoplasia 2(2):100086, 2025. e-Pub 2025. PMID: 40453135.
7. Chien KS, Braish JS, Li Z, Loghavi S, Bataller A, Montalban-Bravo G, Sasaki K, Kanagal-Shamanna R, Takahashi K, DiNardo CD, Swaminathan M, Kantarjian HM, Garcia-Manero G. Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. Leukemia 39(5):1269-1272, 2025. e-Pub 2025. PMID: 40175627.
8. Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Kadia TM, Borthakur G, Daver N, Short NJ, Jain N, Issa GC, Haddad F, Hammond D, Chien K, Tang G, Thakral B, Montalban-Bravo G, Pemmaraju N, Bazinet A, Swaminathan M, Pierce S, Abbas HA, Reville P, Popat U, Shpall E, Champlin R, Jabbour E, Ravandi F, Kantarjian HM, DiNardo CD. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies. Am J Hematol 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
9. Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J 15(1):68, 2025. e-Pub 2025. PMID: 40246832.
10. Swaminathan M, DiNardo CD, Maiti A, Pemmaraju N, Ohanian M, Daver NG, Garcia-Manero G, Issa GC, Borthakur G, Ravandi F, Montalban-Bravo G, Kadia TM, Alvarado Y, Jabbour EJ, Short NJ, Wierda WG, Jain N, Kornblau SM, Masarova L, Pierce SA, Qiao W, Ning J, Kantarjian H, Konopleva MY. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial. Blood Cancer J 15(1):52, 2025. e-Pub 2025. PMID: 40175328.
11. DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
12. Bataller A, Sasaki K, Urrutia S, Montalban-Bravo G, Bazinet A, Chien K, Hammond D, Bouligny IM, Swaminathan M, Issa G, Short N, Daver N, DiNardo CD, Kadia T, Jabbour E, Ravandi F, Roboz GJ, Savona M, Griffiths EA, McCloskey J, Odenike O, Oganesian A, Keer HN, Azab M, Kantarjian H, Garcia-Manero G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. Blood Cancer J 15(1):50, 2025. e-Pub 2025. PMID: 40164584.
13. DiNardo CD, Jen W, Takahashi K, Kadia TM, Daver NG, Reville PK, Issa GC, Short NJ, Sasaki K, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Kantarjian HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia | Leukemia. Springer Nature, 2025. e-Pub 2025.
14. Jen WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McCue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti A, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1):e35662, 2025. e-Pub 2025. PMID: 39584789.
15. Marvin-Peek J, Shelton V, Brassil K, Fellman B, Barr A, Chien KS, Hammond D, Swaminathan M, Jain N, Wierda W, Ferrajoli A, DiNardo C. Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial. Acta Haematol 148(2):233-243, 2025. e-Pub 2025. PMID: 38861934.
16. Wei-Ying Jen BM, BCh, Jennifer Marvin-Peek MD, Hagop M Kantarjian MD, Yesid Alvarado MD, Gautam Borthakur MD, Elias Jabbour MD, William Wierda MD, Tapan M Kadia MD, Naval G Daver MD, Courtney D DiNardo MD, Nicholas J Short MD, Nitin Jain MD, Alessandra Ferrajoli MD, Steven Kornblau MD, Musa Yilmaz MD, Maro Ohanian MD, BSc DM, Jan Burger MD, Danielle Hammond MD, Keyur Patel MD, Ghayas C Issa MD, Naveen Pemmaraju MD, Koji Sasaki MD, Abhishek Maiti MD, Hussein A Abbas MD, Kelly Chien MD, Koichi Takahashi MD, Fadi Haddad MD, Prithviraj Bose MD, Lucia Masarova MD, Guillermo Montalban-Bravo MD, Mahesh Swaminathan MD, Mark Brandt BS, Sherry Pierce BA, BSN, Guillermo Garcia-Manero MD, Farhad Ravandi MD. Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia in Cancer. American Cancer Society, 2024. e-Pub 2024.
17. Singh, A, Trinchant, NM, Mishra, R, Arora, K, Mehta, S, Kuzmanovic, T, Zokaei Nikoo, M, Singh, I, Przespolewski, A, Swaminathan, M, Ernstoff, MS, Dy, GK, Yan, LB, Sinha, E, Sharma, S, Hassane, DC, Griffiths, EA, Wang, ES, Guzman, ML, Thota, S. Immune Checkpoint Inhibitor Therapy and Associations with Clonal Hematopoiesis †. International journal of molecular sciences 25(20), 2024. e-Pub 2024. PMID: 39456832.
18. Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv 8(10):2342-2350, 2024. e-Pub 2024. PMID: 38537065.
19. Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
20. Swaminathan M, Aly MM, Khan AM, Share BA, Dhillon V, Lalo E, Ramos H, Akers KG, Kim S, Balasubramanian S. Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. EJHaem 4(1):165-173, 2023. e-Pub 2023. PMID: 36819163.
21. Swaminathan M, Cortes JE. Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. Therapeutic Advances in Hematology 14, 2023. e-Pub 2023.
22. Singh A, Mencia-Trinchant N, Griffiths EA, Altahan A, Swaminathan M, Gupta M, Gravina M, Tajammal R, Faber MG, Yan L, Sinha E, Hassane DC, Hayes DN, Guzman ML, Iyer R, Wang ES, Thota S. Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. JCO Precis Oncol 6:e2100309, 2022. e-Pub 2022. PMID: 35025619.
23. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
24. Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma 60(9):2207-2213, 2019. e-Pub 2019. PMID: 30773968.
25. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1767-1774, 2019. e-Pub 2019. PMID: 30632841.
26. Swaminathan M, Patel KP, Huynh-Lu J, Tang G, Zuo Z, Miranda R, Verstovsek S. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript. Acta Haematol 141(1):23-27, 2019. e-Pub 2019. PMID: 30463063.
27. Bose P, Swaminathan M. Janus kinase inhibition and symptom control in myeloproliferative neoplasms. Curr Med Res Opin 34(5):935-937, 2018. e-Pub 2018. PMID: 29415577.
28. Abeer, A, Swaminathan, M, Kumar, J. Sweet Mystery Case Report of a Rare Presentation of Myelodysplastic Syndrome as the Sweet’s Syndrome. Scientific Open Access 1(1):3, 2017. e-Pub 2017.
29. Swaminathan, m, Jensen, T, Ray, T, Andruska, N, Shah, A, Egner, J, Ray P. FOXC1 expression in acute myeloid leukemia: potential predictor of disease relapse and/or refractory disease 128(22):5260, 2016. e-Pub 2016.

Review Articles

1. Swaminathan M, Jain A, Choi SD, Pemmaraju N. Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what's the current standard of care?. Expert Rev Hematol 17(11):769-780, 2024. e-Pub 2024. PMID: 39344987.
2. Swaminathan M, Cortes JE. Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. Ther Adv Hematol 14:20406207231154708, 2023. e-Pub 2023. PMID: 36845850.
3. Swaminathan M, Bourgeois W, Armstrong SA, Wang ES. Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?. Cancer J 28(1):62-66, 2022. e-Pub 2022. PMID: 35072375.
4. Swaminathan M, Wang ES. Novel therapies for AML: a round-up for clinicians. Expert Rev Clin Pharmacol 13(12):1389-1400, 2020. e-Pub 2020. PMID: 33412978.
5. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud 5(1), 2019. e-Pub 2019. PMID: 30709875.

Editorials

1. Swaminathan M, Ravandi F. Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?. Haematologica 108(10):2561-2563, 2023. PMID: 37345488.

Abstracts

1. Swaminathan M. Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL. American Society of Hematology, 2025. e-Pub 2025.
2. Swaminathan, M, Fazal, S, Griffiths, E, Thompson, J, Sung, PJ, Green, SD, Li, E, Said, M, Belko, K, Mattice, E, Attwood, K, Wang, E. A phase II study of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: Trial in progress, 2022. e-Pub 2022.
3. Swaminathan M, Fazal S, Griffiths E, Thompson J, Sung PJ, Green SD, Li E, Said M, Belko K, Mattice E, Attwood K, Wang E. A phase II study of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: Trial in progress. Presented at ASH, 2022. e-Pub 2022.
4. Aly, MM, Swaminathan, M, Akers, K, Kim, S, Ramos, H, Maciejewski, J, Balasubramanian, SK. A Systematic Review and Meta-Analysis Comparing Type I and II FLT3 Inhibitors in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome 138(Suppl 1), 2021. e-Pub 2021.
5. Swaminathan, S, Aly, MM, Akers, K, Kijm, S, Balasubramanian, S. Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome – a systematic review and meta-analysis, 2021. e-Pub 2021.
6. Swaminathan, M, Przespolewski, A, Griffiths, E, Thompson, J, Elshoury, A, Walinski, W, Wang, E. Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia 138(Suppl 1), 2021. e-Pub 2021.
7. Swaminathan, M, Przespolewski, A, Griffiths, E, Thompson, J, Elshoury, A, Walinski, W, Said, M, Halliwell, S, Puff, C, Attwood, K, Wang, E. Phase I Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia 138(Suppl 1), 2021. e-Pub 2021.
8. Singh, A, Mencia-Trinchant, N, Griffiths, EA, Swaminathan, M, Gravina, M, Tajammal, R, Faber, M, Ernstoff, M, Yan, L, Sinha, E, Herr, M, Hassane, D, Guzman, M, Przespolewski, A, Wang, E, Thota, S. DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitor 138(Suppl 1), 2021. e-Pub 2021.
9. Aly MM, Swaminathan M, Akers K, Kim S, Ramos H, Maciejewski J, Balasubramanian SK. A Systematic Review and Meta-Analysis Comparing Type I and II FLT3 Inhibitors in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 138(Suppl 1), 2021. e-Pub 2021.
10. Swaminathan M, Przespolewski A, Griffiths E, Thompson J, Elshoury A, Walinski W, Wang E. Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood 138(Suppl 1), 2021. e-Pub 2021.
11. Swaminathan M, Przespolewski A, Griffiths E, Thompson J, Elshoury A, Walinski W, Said M, Halliwell S, Puff C, Attwood K, Wang E. Phase I Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia. Blood 138(Suppl 1), 2021. e-Pub 2021.
12. Singh A, Mencia-Trinchant N, Griffiths EA, Swaminathan M, Gravina M, Tajammal R, Faber M, Ernstoff M, Yan L, Sinha E, Herr M, Hassane D, Guzman M, Przespolewski A, Wang E, Thota S. DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitor. Blood 138(Suppl 1), 2021. e-Pub 2021.
13. Pandey, M, Swaminathan, M, Griffiths, E, Thompson, J, Przespolewski, A, Thota, S, Baron, J, Cronin, T, Wang, E. Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+ 3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis 134(Suppl 1), 2019. e-Pub 2019.
14. Pandey M, Swaminathan M, Griffiths E, Thompson J, Przespolewski A, Thota S, Baron, J, Cronin T, Wang E. Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+ 3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis. Blood 134(Suppl 1), 2019. e-Pub 2019.
15. Swaminathan, M, Jabbour, E, Ravandi, F, Kadia, T, Borthakur, G, Konopleva, M, DiNardo, C, Pierce, S, Alvarado, Y, Assi, RE, Dalle, I, Tallis, E, Kantarjain, H, Garcia-Manero, G. Outcomes of Patients with Nucleoplasmin-1 Mutated Acute Myeloid Leukemia Treated With Hypomethylating Agents 36(15):7054, 2018. e-Pub 2018.
16. Swaminathan, M, Jabbour, E, Ravandi, F, Kadia, T, Borthakur, G, Short, NJ, Poerce, S, Waukau, J, Miller, D, Cortes, J, Alvarado, Y, Kantarjian, H, Garcia-Manero, G. Association of early intervention in transfusion independent patients with lower-risk myelodysplastic syndromes treated with attenuated doses of hypomethylating agents with high response rates and long duration of response 36(15):7001, 2018. e-Pub 2018.
17. Boddu, P, Swaminathan, M Ravandi M, F, Garcia-Manero, G, Borthakur, G, Jabbour, E, DiNardo, C, Daver, N, Jain. Prognostic Implications of Minimal Residual Disease Detection in Acute Myeloid Leukemia (AML) with Cytarabine Based Therapy of Differing Dose Intensities 130(Suppl 1), 2017. e-Pub 2017.
18. Swaminathan, M, Knatarjain, H, Daver, N, Borthakur, B, Ohanian, M, Kadia, T, DiNardo, C, Jain, N, Estrov, Z, Ferrajoli, A, Garcia-Manero, G, Konopleva, M, Andreeff, M, Pemmaraju, N, Jabbour, E, Wierda, W, Pinsoy, MR, Cortes, J. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial 130(Suppl 1):723, 2017. e-Pub 2017.
19. Swaminathan M, Kantarjian H, Daver N, Borthakur B, Ohanian M, Kadia T, DiNardo C, Jain N, Estrov Z, Ferrajoli A, Garcia-Manero G, Konopleva M, Andreeff M, Pemmaraju N, Jabbour E, Wierda W, Pinsoy MR, Cortes J. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood 130(Suppl 1):723, 2017. e-Pub 2017.
20. Boddu P, Swaminathan M, Ravandi F, Garcia-Manero G, Borthakur G, Jabbour E, DiNardo C, Daver N, Jain N. Prognostic Implications of Minimal Residual Disease Detection in Acute Myeloid Leukemia (AML) with Cytarabine Based Therapy of Differing Dose Intensities. Blood 130(Suppl 1), 2017. e-Pub 2017.
21. Swaminathan, M, Zhang, M. A Rare Case of IgM Multiple Myeloma, 2015. e-Pub 2015.
22. Swaminathan M. Area deprivation index does not influence survival in patients with lower-risk myelodysplastic syndromes at a major cancer center. American Society of Hematology.
23. Swaminathan M. Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center. American Society of Hematology.
24. Swaminathan M. Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center. American Society of Hematology.
25. Swaminathan M. Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials. American Society of Hematology.

Book Chapters

1. Swaminathan, M, Naqvi, K. What the Intensivist Needs to Know About Leukemia Patients. In: Oncologic Critical Care, 1489-1497, 2019.

Letters to the Editor

1. Chien KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, Hammond DE, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Dong XQ, Pierce SA, Huang X, Jabbour EJ, Kantarjian HM, Garcia-Manero G. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leuk Res 147: 107602, 2024.

Web Publications

1. Swaminathan M, Alessandra Ferrajoli. Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia?.